Key result
Intracoronary bone marrow mononuclear cells delivered 3 or 7 days after STEMI did not significantly improve left ventricular ejection fraction at 6 months compared with placebo (48.3% vs 47.8%; P=.96).
Why the study?
Does intracoronary autologous bone marrow mononuclear cell delivery improve left ventricular function in patients with left ventricular dysfunction after successful primary PCI for anterior STEMI?
RCT (n=120)
Double-blind
2x2 factorial
Yes
Does intracoronary autologous bone marrow mononuclear cell delivery improve left ventricular function in patients with left ventricular dysfunction after successful primary PCI for anterior STEMI?
Absolute Event Rate: 48.3% vs 47.8%
p-value: p=.96
Intracoronary delivery of autologous bone marrow mononuclear cells at 3 or 7 days after primary PCI for anterior STEMI does not improve global or regional left ventricular function.
No takes yet. Share an insight, caveat, or question.
Intracoronary bone marrow mononuclear cells should not be used after STEMI; confirms no LVEF benefit in this RCT.
Traverse et al. (2012) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=120). Intracoronary autologous bone marrow mononuclear cells (BMCs) vs. Placebo was evaluated on Change in global (LVEF) and regional (wall motion) left ventricular function in infarct and border zones at 6 months (p=.96). Intracoronary bone marrow mononuclear cells delivered 3 or 7 days after STEMI did not significantly improve left ventricular ejection fraction at 6 months compared with placebo (48.3% vs 47.8%; P=.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: